RxDoctor Payments Data

Noeli Pinelo Nicholson, MD

Family Medicine · Fort Myers, FLNPI 1053806117

Payments from drug & device makers

$2,710in general payments, 2019–2025

Across 143 payments — averaging $18.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$600
  • Lilly USA, LLC$300
  • GSK$245
  • AstraZeneca$221
  • Pfizer$214
  • Novo Nordisk$197
  • plus $932 from 18 others

What the payments were for

  • Food & beverage$2,66598%
  • Education$452%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,710 in reported general payments places this provider in the 80th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$348,466
Medicare patients
569
Services billed
5,684

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide52$64,712
FarxigaDapagliflozin Propanediol47$47,715
MounjaroTirzepatide37$43,062
EliquisApixaban33$42,634
RybelsusSemaglutide26$40,254
XareltoRivaroxaban14$21,841
JardianceEmpagliflozin12$16,625
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$11,142
SynthroidLevothyroxine Sodium86$8,166
Rosuvastatin Calcium400$4,445
ShingrixVaricella-Zoster Ge/As01b/Pf12$2,673
Atorvastatin Calcium222$2,184
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate12$1,979
Levothyroxine Sodium235$1,794
Ezetimibe81$1,721

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$197$104,96678 claims
AstraZenecaFarxiga$221$47,71547 claims
Lilly USA, LLCMounjaro$300$43,06237 claims
PfizerEliquis$214$42,63433 claims
Johnson & JohnsonXarelto$72$21,84114 claims
GSKTrelegy Ellipta, Shingrix$245$13,81628 claims
AbbVieSynthroid, Armour Thyroid$600$8,90197 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Fort Myers

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →